Corcept Therapeutics (CORT) Total Liabilities (2010 - 2026)

Corcept Therapeutics has disclosed Total Liabilities across 17 years of filings, most recently posting $176.9 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $176.9 million, up 8.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $176.9 million (up 8.41% YoY), and the FY2025 annual result was $188.8 million, up 17.32% from the prior year.
• Total Liabilities came in at $176.9 million for Q1 2026 at Corcept Therapeutics, down from $188.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $191.7 million in Q3 2025 to a low of $54.0 million in Q2 2022.
• The 5-year median for Total Liabilities is $118.3 million (2024), against an average of $124.3 million.
• Across the five-year window, Total Liabilities soared 120.97% in 2023 and rose 8.41% in 2026, its largest moves.
• Corcept Therapeutics' Total Liabilities stood at $81.6 million in 2022, then soared by 40.72% to $114.8 million in 2023, then soared by 40.2% to $161.0 million in 2024, then climbed by 17.32% to $188.8 million in 2025, then fell by 6.33% to $176.9 million in 2026.
• The last three Total Liabilities figures came in at $176.9 million (Q1 2026), $188.8 million (Q4 2025), and $191.7 million (Q3 2025), per Business Quant data.